Related Content
Search Google Scholar for:
|
|
Science 14 December 1973: Vol. 182. no. 4117, pp. 1146 - 1148 DOI: 10.1126/science.182.4117.1146
|
|
Articles
Polyol Accumulation in Galactosemic and Diabetic Rats: Control by an Aldose Reductase Inhibitor
D. Dvornik 1,
N. Simard-Duquesne 1,
M. Krami 1,
K. Sestanj 1,
K. H. Gabbay 2,
J. H. Kinoshita 3,
S. D. Varma 3, and
L. O. Merola 3
1 Department of Biochemistry, Ayerst Research Laboratories, Montreal, Quebec, Canada
2 Cell Biology, Laboratory, Endocrine Division, Children's Hospital Medical Center, Boston, Massachusetts 02115, and Department of Pediatrics, Harvard Medical School, Boston
3 Laboratory of Vision Research, National Eye Institute, Bethesda, Maryland 20015
An orally active inhibitor of aldose reductase, 1,3-dioxo-1H-benz[de]-isoquinoline-2(3H)acetic acid (AY-22,284), prevented cataractous changes in cultured lenses exposed to high concentrations of galactose. When given orally, AY-22,284 markedly decreased the accumulation of polyols in the lenses and sciatic nerves of galactosemic rats and rats with streptozotocin-induced diabetes. In addition, treatment of galactosemic rats with AY-22,284 effectively suppressed the formation of cataracts.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products.
- Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, T. C. B. Moore, J. Moore, Y. Yamamoto, H. Yamamoto, and A. P. Adamis (2007)
Invest. Ophthalmol. Vis. Sci.
48, 858-865
| Abstract »
| Full Text »
| PDF »
- Molecular Structure of Human Galactokinase: IMPLICATIONS FOR TYPE II GALACTOSEMIA.
- J. B. Thoden, D. J. Timson, R. J. Reece, and H. M. Holden (2005)
J. Biol. Chem.
280, 9662-9670
| Abstract »
| Full Text »
| PDF »
- Molecular Structure of Human Galactose Mutarotase.
- J. B. Thoden, D. J. Timson, R. J. Reece, and H. M. Holden (2004)
J. Biol. Chem.
279, 23431-23437
| Abstract »
| Full Text »
| PDF »
- Topical Review : New Trends in the Etiopathogenesis of Diabetic Peripheral Neuropathy.
- A. Verrotti, T. Giuva, G. Morgese, and F. Chiarelli (2001)
J Child Neurol
16, 389-394
| Abstract »
| PDF »
- Contributions of polyol pathway to oxidative stress in diabetic cataract.
- A. Y. W. lee and S. S. M. Chung (1999)
FASEB J
13, 23-30
| Abstract »
| Full Text »
- An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
- D. Wilson, K. Bohren, K. Gabbay, and F. Quiocho (1992)
Science
257, 81-84
| Abstract »
| PDF »
- A Randomized Trial of Sorbinil, an Aldose Reductase Inhibitor, in Diabetic Retinopathy.
- Sorbinil Retinopathy Trial Research Group (1990)
Arch Ophthalmol
108, 1234-1244
| Abstract »
| PDF »
- Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
- W. Williams and J. Odom (1986)
Science
233, 223-225
| Abstract »
| PDF »
- Polyol Pathway Metabolites in Human Cataracts: Correlation of Circulating Glycosylated Hemoglobin Content and Fasting Blood Glucose Levels.
- B. C. Lerner, S. D. Varma, and R. D. Richards (1984)
Arch Ophthalmol
102, 917-920
| Abstract »
| PDF »
- Aldose Reductase in Diabetic Cataracts.
- J. H. Kinoshita, P. Kador, and M. Catiles (1981)
JAMA
246, 257-261
| Abstract »
| PDF »
- Effect of an Aldose Reductase Inhibitor on Diabetic Peripheral Neuropathy: Preliminary Report.
- A. Culebras, J. Alio, J.-L. Herrera, and M. I. P. Lopez-Fraile (1981)
Arch Neurol
38, 133-134
| Abstract »
| PDF »
- Diabetic cataracts and flavonoids.
- S. Varma, A Mizuno, and J. Kinoshita (1977)
Science
195, 205-206
| Abstract »
| PDF »
- Flavonoids as inhibitors of lens aldose reductase.
- S. Varma, I Mikuni, and J. Kinoshita (1975)
Science
188, 1215-1216
| Abstract »
| PDF »
|
|